For Active Pharmaceutical Ingredient (API) manufacturers, the consistent availability of high-purity intermediates is non-negotiable. Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate (CAS: 161798-02-3) is a prime example of such a critical compound, serving as a key intermediate in the synthesis of Febuxostat. Febuxostat, a widely recognized treatment for hyperuricemia and gout, requires intermediates that meet rigorous quality specifications to ensure the safety and efficacy of the final drug product.

As a leading manufacturer and supplier of pharmaceutical intermediates in China, we understand the paramount importance of both purity and supply stability. Our production process for Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate is meticulously controlled to achieve an assay of u226598.0%, with a physical form of white to off-white powder. This high level of purity is essential for preventing unwanted side reactions and ensuring a high yield in subsequent synthesis steps, directly impacting the cost-effectiveness of API production.

The challenge for API manufacturers often lies in securing a reliable and consistent supply. Fluctuations in quality or availability can lead to significant delays and increased costs. We mitigate this risk by maintaining robust inventory levels and having a well-established manufacturing capacity. When you choose to buy this Febuxostat intermediate from us, you are partnering with a supplier committed to long-term stability and predictable delivery.

Furthermore, our direct manufacturer-to-buyer model allows for competitive pricing, especially for bulk orders. This economic advantage is crucial in the highly competitive pharmaceutical market. We encourage R&D scientists and procurement managers to contact us to obtain a quotation for large-volume purchases, ensuring that you can source this vital intermediate efficiently and affordably.

In essence, securing a dependable supply of high-quality Ethyl 2-(3-cyano-4-hydroxyphenyl)-4-methylthiazole-5-carboxylate is a strategic decision for any API manufacturer involved in Febuxostat production. Our commitment to quality assurance, production capacity, and customer service makes us an ideal partner for meeting these critical needs. We are ready to support your manufacturing goals with this essential pharmaceutical building block.